PrimeGen Biotech LLC has created a wholly owned subsidiary -- PrimeCell Therapeutics LLC -- to work exclusively on the therapeutic development of PrimeCell, the first adult, non-embryonic stem cell capable of transforming into any cell type found in the body.

According to the company release, PrimeCell Therapeutics will focus solely on adult stem cell reprogramming, and preparing PrimeCell for therapeutic development and application. To date, using therapeutic reprogramming technology, human germ cells have been successfully transformed into human heart, brain, bone and cartilage cells. The PrimeCell findings currently are undergoing peer review, and the company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.

Consolidating PrimeCell operations under a separate entity is designed to help the company move quickly from research to therapy, as researchers work to provide reprogrammed PrimeCells for cell-based therapies to treat a range of life-threatening conditions.

"Work on PrimeCell has progressed remarkably fast, and we believe the establishment of PrimeCell Therapeutics will help us expedite our efforts to provide PrimeCells for a host of cell-based therapies," Thomas C.K. Yuen, PrimeGen chairman and CEO said adding, "PrimeGen will continue its pursuit of the best approaches across the range of regenerative medicine, while PrimeCell Therapeutics will focus entirely on what we believe to be the most promising methodology yet -- a germ line stem cell reprogrammed to be pluripotent."

PrimeGen will license to PrimeCell Therapeutics all of the intellectual property assets as necessary for the new company to develop the PrimeCell technology.